KRAS mutation analysis on cytological specimens of metastatic colo‐rectal cancer
- 19 November 2010
- journal article
- research article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 38 (12) , 869-873
Abstract
Recent evidences showed that metastatic colorectal cancer (CRC) patients with tumors harboring a KRAS gene mutation do not derive benefit from the administration of epidermal growth factor receptor‐directed monoclonal antibodies. Typically, the specimens available for KRAS mutational analysis are formalin‐fixed paraffin‐embedded (FFPE) primary tumor tissue blocks. However, in patients with rectal tumours undergoing neoadjuvant therapy, the source of FFPE material is limited. In this setting, CRC cytological samples taken from the metastatic site may be exploited. However, these specimens show at least some degree of necrosis; thus, their suitability for the KRAS assay needs to be tested. Here, we show that 18/19 (94.7%) metastatic CRC smears were perfectly adequate for codon 12 and 13 KRAS mutational analysis by direct gene sequencing. Only one case (5.3%) showing abundant necrotic debris and poor cellular preservation was not informative for KRAS status. Codon 12 gene mutations were found in 4/18 (22.2%) of the adequate cases (c35G>T n = 2; c34G>T n = 1; c35G>A n = 1). Concordance between cytological and FFPE samples, both available in 13 patients, occurred in 92.3% (12/13) of the cases. Thus, whenever histological specimens of CRC are notavailable, KRAS testing may be reliably performed on cytological specimens. Diagn. Cytopathol. 2010;38:869–873.Keywords
This publication has 13 references indexed in Scilit:
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient SelectionJournal of Clinical Oncology, 2009
- Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapyCancer, 2009
- Setting Future Standards for KRAS Testing in Colorectal CancerPharmacogenomics, 2008
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programVirchows Archiv, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- EGFR Antagonists in Cancer TreatmentNew England Journal of Medicine, 2008
- Diagnostic utility of CDX-2 expression in separating metastatic gastrointestinal adenocarcinoma from other metastatic adenocarcinoma in fine-needle aspiration cytology using cell blocksCancer, 2004
- Cytologic Features of Colonic AdenocarcinomaActa Cytologica, 1997
- ras GENESAnnual Review of Biochemistry, 1987